Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose of capecitabine and oral navelbine that
can be given without causing severe side effects, and to determine the safety, tolerability,
and effects (good and bad) of capecitabine given with oral navelbine to patients with
advanced breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital